Coleman Mark 4
4 · Axsome Therapeutics, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Axsome (AXSM) Director Mark Coleman Receives RSU Award
What Happened
Mark Coleman, a director of Axsome Therapeutics (AXSM), received an award of 1,721 restricted stock units (RSUs) on June 5, 2026. The RSUs were reported as acquired at $0.00 (no cash paid); each RSU represents the contingent right to one share and the award vests in full one year after the grant date.
Key Details
- Transaction date: 2026-06-05 (reported on Form 4 filed 2026-06-09).
- Transaction type/code: Award/Grant (A) of RSUs (derivative), 1,721 units, acquisition price $0.00.
- Vesting: RSUs vest in full on the one-year anniversary of the grant (per footnote).
- Shares owned after transaction: Not specified in the provided filing.
- Timeliness: Filed 2026-06-09, within the typical two-business-day reporting window for Form 4.
Context
This was a compensation grant (RSUs), not an open-market purchase or sale. RSUs are contingent — they convert to actual shares only upon vesting (here, one year later) and typically reflect routine director compensation rather than an immediate directional bet on the stock. There were no sales, exercises, or cash proceeds reported in this transaction.
Insider Transaction Report
- Award
Restricted Stock Units
[F1][F2]2026-06-05+1,721→ 1,721 total→ Common Stock (1,721 underlying)
Footnotes (2)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The RSUs vest in full on the one-year anniversary of the date of grant.